Try our Advanced Search for more refined results
Life Sciences
-
December 16, 2025
Dana-Farber To Pay $15M To Resolve Fraud Allegations
Dana-Farber Cancer Institute will pay $15 million to settle allegations that its researchers used inaccurate images in grant applications and research articles, the U.S. Department of Justice announced Tuesday.
-
December 16, 2025
Ex-NIAID Director Claims Retaliation in Trump Admin Suit
The former director of the National Institute of Allergy and Infectious Diseases filed suit in Maryland federal court on Tuesday alleging Trump administration appointees violated her constitutional rights by illegally terminating her employment and that she cannot expect her claims to be fairly heard by the "undermined" U.S. Office of Special Counsel.
-
December 16, 2025
Samsung Wants ITC To Consider Oura Smart Ring IP Fight
Samsung has expanded its legal battle with Oura over patents covering biometric-tracking wearable technologies, telling the U.S. International Trade Commission that Oura's smart rings infringe a set of four patents owned by Samsung.
-
December 16, 2025
PE-Backed Medline Prices Long-Awaited $6.3B IPO
Private equity-backed medical supplies giant Medline, guided by Simpson Thacher & Bartlett LLP, on Tuesday priced an upsized initial public offering, raising $6.26 billion in what will be the largest IPO of 2025 just weeks before year-end.
-
December 16, 2025
Ultrahuman Loses Bids To Halt ITC Order In Oura Patent Case
The U.S. International Trade Commission and the Federal Circuit have both denied requests by Ultrahuman to stay ITC orders barring imports of its smart rings found to infringe an Ouraring patent, turning aside Ultrahuman's arguments that the orders are too broad.
-
December 16, 2025
DOD To Reevaluate Discharges Over COVID Vax Refusal
The U.S. Department of Defense said on Tuesday that Secretary of Defense Pete Hegseth ordered a reevaluation of the discharge status of service members who were involuntarily removed from the military after they refused to receive the COVID-19 vaccine.
-
December 16, 2025
Vax Skeptics Cite High Court In New Challenge To NY Mandate
A vaccine skepticism advocacy group once tied to Secretary of Health and Human Services Robert F. Kennedy Jr. is revamping its fight against New York's school vaccination mandate, arguing recent activity by the U.S. Supreme Court necessitates a fresh analysis.
-
December 16, 2025
PTAB Cuts X-Ray Patent Claims After Fed. Circ. Remand
The Patent Trial and Appeal Board has found that three claims that Sigray Inc. challenged in a Carl Zeiss X-Ray Microscopy Inc. X-ray imaging patent were invalid after the Federal Circuit told it to take another look at the claims.
-
December 16, 2025
Va. Judge Advances Most Claims In Stelara Antitrust Case
A Virginia federal judge has allowed health insurer CareFirst's anticompetition and patent fraud claims against Johnson & Johnson to move forward in a case alleging anticompetitive behavior in relation to the immunosuppressive drug Stelara, while letting the pharmaceutical giant escape some claims of misrepresentation.
-
December 16, 2025
Trump Executive Order Calls Fentanyl A 'WMD'
President Donald Trump has declared fentanyl a "weapon of mass destruction," according to an executive order that explicitly calls on the military to respond to "chemical incidents in the homeland."
-
December 16, 2025
The Most Important Healthcare And Life Science Deals Of 2025
Attorneys taking stock of 2025 spoke to Law360 about the most important deals of the year, including Pfizer’s high-profile acquisition of Metsera and transactions in outpatient services and gene therapy.
-
December 16, 2025
Trends That Shaped Healthcare Dealmaking In 2025
With 2025 coming to a close, Law360 Healthcare Authority asked attorneys focused on healthcare deals for their take on the trends that influenced dealmaking over the last 12 months.
-
December 16, 2025
Merck Sued Over Time Rounding, OT Averaging At NC Plant
A Merck manufacturing facility in North Carolina rounded workers' time to short them on pay, averaged out overtime across two weeks and fired an operator technician because of his sleep apnea, the worker told a federal court in a proposed class and collective action against the pharmaceutical giant.
-
December 16, 2025
Jury Says Magnolia Medical Is Owed $1.6M After Patent Trial
A Delaware federal jury on Tuesday morning found that Magnolia Medical Technologies Inc. is entitled to nearly $1.6 million after Kurin Inc. infringed its patents tied to devices meant for drawing blood.
-
December 16, 2025
5 Big Litigation Developments Out Of Georgia In 2025
It was a busy year for courts in Georgia, with a federal judge ordering the state's corrections system to continue providing hormone therapy to transgender people in prison, and prosecutors deciding to drop the historic racketeering case against President Donald Trump and his allies. Here, Law360 recaps the biggest legal developments to come out of Peach State courts in 2025.
-
December 16, 2025
Another Dechert IP Atty Leaves, This Time For Morgan Lewis
Morgan Lewis LLP has added another departing member of the Dechert LLP intellectual property team, who joins the firm in Boston after Dechert's global intellectual property practice co-chair, two partners, and a total of 30 professionals moved to Cooley LLP last week.
-
December 16, 2025
Medical Device Maker Zynex Hits Ch. 11 With Sale Plans
Zynex Inc., a pain management medical device maker, filed for bankruptcy protection in Texas with at least $66.7 million in debt and plans to sell the business backed by a stalking horse bid from its creditors.
-
December 15, 2025
Smartwatch Giants Sued Over Fall Detection Patents
A company that makes medical alert watches for the elderly has sued Apple, Samsung, Google and Garmin in federal court and the U.S. International Trade Commission, alleging that the fall detection features in their smartwatches infringe two patents.
-
December 15, 2025
States Fight Sandoz Bid To Argue Duplication In Generics Row
Multiple attorneys general have told a Connecticut federal court that Sandoz Inc. and Fougera Pharmaceuticals Inc. can't claim the states' grievances over allegations of price fixing are duplicative of claims that were already settled, since there are some claims and forms of relief that only state plaintiffs can seek.
-
December 15, 2025
DOJ Raises Accreditation Concerns In Vet School Case
The U.S. Department of Justice waded into a Tennessee veterinary school's antitrust case challenging the American Veterinary Medical Association's accreditation requirements, raising concerns about the risk posed by professional groups that play gatekeeping functions.
-
December 15, 2025
Ohio Gov. To Designate Synthetic Kratom Extract Illegal Drug
Ohio Gov. Mike DeWine is looking to immediately ban synthetic kratom compounds while simultaneously seeking to either ban or heavily regulate the active ingredient in "natural kratom," citing serious public health concerns.
-
December 15, 2025
Formula Suits An 'Undue Burden' On Cook County, Panel Says
An Illinois appellate court Friday agreed with Abbott Laboratories that 23 lawsuits alleging the company failed to warn of important risks associated with infant formulas and caused premature babies to develop necrotizing enterocolitis should not have been filed in Cook County, where the infants at the center of those cases were not born and have never lived.
-
December 15, 2025
USPTO Replaces Denver Office With Center In Montana
Montana has been picked by the U.S. Patent and Trademark Office to be the first state to oversee community outreach in the area formerly serviced by the now-shuttered Rocky Mountain Regional Outreach Office in Denver.
-
December 15, 2025
Cencora Pays $5B For Majority Stake Of OneOncology
Pharmaceutical company Cencora Inc. unveiled plans Monday to acquire a majority stake in cancer care company OneOncology for $5 billion, buying interest from private equity shop TPG in a deal built by three law firms.
-
December 15, 2025
Connecticut 'Likely' To Settle Generic Drug Price Cap Dispute
A pharmaceutical industry trade group and the state of Connecticut have signaled their intent to settle a feud over the interpretation of the state's generic drug price cap law, and a federal judge gave them until Monday to say more about their plan.
Expert Analysis
-
2 Fed. Circ. Rulings Underscore Patent Prosecution Pitfalls
Two recent patent decisions from the Federal Circuit, overturning significant judgments, serve as reminders that claim modifications and cancellations may have substantive effects on the scope of other claims, and that arguments distinguishing prior art and characterizing claims may also limit claim scope, say attorneys at Morgan Lewis.
-
Rebutting Price Impact In Securities Class Actions
Defendants litigating securities cases historically faced long odds in defeating class certification, but that paradigm has recently begun to shift, with recent cases ushering in a more searching analysis of price impact and changing the evidence courts can consider at the class certification stage, say attorneys at Katten.
-
7 Document Review Concepts New Attorneys Need To Know
For new associates joining firms this fall, stepping into the world of e-discovery can feel like learning a new language, but understanding a handful of fundamentals — from coding layouts to metadata — can help attorneys become fluent in document review, says Ann Motl at Bowman and Brooke.
-
Ruling On Labor Peace Law Marks Shift For Cannabis Cos.
Currently on appeal to the Ninth Circuit, an Oregon federal court’s novel decision in Casala v. Kotek, invalidating a state law that requires labor peace agreements as a condition of cannabis business licensure, marks the potential for compliance uncertainty for all cannabis employers in states with labor peace mandates, say attorneys at Sheppard Mullin.
-
Fed. Circ. Rulings Refine Patent Claim Construction Standards
Four Federal Circuit patent decisions this year clarify several crucial principles governing patent claim construction, including the importance of prosecution history, and the need for error-free, precise language from claims drafters, say attorneys at Taft.
-
How Value-Based Patent Fees May Shape IP Strategies
If the U.S. Patent and Trademark Office implements rumored plans to correlate patent fees with patent value, the financial and strategic consequences would largely depend on the specifics of how, when and how often patent values are assessed, say attorneys at Cleary.
-
Agentic AI Puts A New Twist On Attorney Ethics Obligations
As lawyers increasingly use autonomous artificial intelligence agents, disciplinary authorities must decide whether attorney responsibility for an AI-caused legal ethics violation is personal or supervisory, and firms must enact strong policies regarding agentic AI use and supervision, says Grace Wynn at HWG.
-
Using Reissue Applications To Strategically Improve Patents
Though reissue applications are an often-overlooked consideration in today's patent environment, they can offer powerful tools for correcting errors, strengthening patent protection, or adapting to evolving business and legal landscapes, says Curtis Powell at Wolf Greenfield.
-
FDA Transparency Plans Raise Investor Disclosure Red Flags
The U.S. Food and Drug Administration’s recently announced intent to publish complete response letters for unapproved drugs and devices implicates certain investor disclosure requirements under securities laws, making it necessary for life sciences and biotech companies to adopt robust controls going forward, say attorneys at Arnold & Porter.
-
Series
Being A Professional Wrestler Makes Me A Better Lawyer
Pursuing my childhood dream of being a professional wrestler has taught me important legal career lessons about communication, adaptability, oral advocacy and professionalism, says Christopher Freiberg at Midwest Disability.
-
Patent Claim Lessons From Fed. Circ.'s Teva Decision
The Federal Circuit's recent decision in Janssen v. Teva is an important precedent for parties drafting patent claims or litigating obviousness where the prior art has potentially overlapping ranges for a claimed element, and may be particularly instructive to patent applicants in the pharmaceutical field, say attorneys at Cooley.
-
Series
Law School's Missed Lessons: Adapting To The Age Of AI
Though law school may not have specifically taught us how to use generative artificial intelligence to help with our daily legal tasks, it did provide us the mental building blocks necessary for adapting to this new technology — and the judgment to discern what shouldn’t be automated, says Pamela Dorian at Cozen O'Connor.
-
Ch. 11 Ruling Voiding $2M Litigation Funding Sends A Warning
A recent Texas bankruptcy court decision that a postconfirmation litigation trust has no obligations to repay a completely drawn down $2 million litigation funding agreement serves as a warning for estate administrators and funders to properly disclose the intended financing, say attorneys at Kleinberg Kaplan.
-
DOJ's Novel Cybersecurity FCA Case Is A Warning To Medtech
The U.S. Department of Justice's recent False Claims Act settlement with Illumina over alleged cybersecurity deficiencies suggests that enforcement agencies and whistleblowers are focusing attention toward cybersecurity in life sciences and medical tech, but also reveals key unanswered questions about the legal viability of such allegations, say attorneys at Morgan Lewis.
-
Future-Proof Patent Law By Starting Talent Pipelines Early
Law firms struggling with a narrow talent pipeline in the intellectual property space should consider beginning their recruitment strategies for potential candidates as early as high school, and raise awareness for career opportunities that do not require a law degree, says Christine Hollis at Marshall Gerstein.